Bangying Su

Corporate Officer/Principal presso Washington University in St. Louis

Consumer Services

Health Technology

Profilo

Bangying Su is currently a Principal at Washington University in St. Louis and a Principal at The University of Alabama.
Previously, Dr. Su worked as a Scientist at Dynamis Therapeutics, Inc. Dr. Su completed their undergraduate degree at Peking University.

Posizioni attive di Bangying Su

Società	Posizione	Inizio
Washington University in St. Louis	Corporate Officer/Principal	25/01/2010
The University of Alabama	Corporate Officer/Principal	25/01/2010

Tutte le posizioni attive di Bangying Su

Precedenti posizioni note di Bangying Su

Società	Posizione	Fine
Dynamis Therapeutics, Inc. Dynamis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dynamis Therapeutics, Inc. operates as a holding company with interests in developing pharmaceuticals and diagnostics. It operates through its subsidiaries Dynamis Pharmaceuticals, Inc. and Dynamis Skin Science. The firm's product DYN 15, a drug candidate that prevents the formation of 3DG, a reactive sugar, as well as decreases the levels of key cytokines that are stimulated in chronic inflammations. The company was founded by Annette M. Tobia on May 21, 1997 and is headquartered in Jenkintown, PA.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Bangying Su

Formazione di Bangying Su

Peking University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Bangying Su

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Dynamis Therapeutics, Inc. Dynamis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dynamis Therapeutics, Inc. operates as a holding company with interests in developing pharmaceuticals and diagnostics. It operates through its subsidiaries Dynamis Pharmaceuticals, Inc. and Dynamis Skin Science. The firm's product DYN 15, a drug candidate that prevents the formation of 3DG, a reactive sugar, as well as decreases the levels of key cytokines that are stimulated in chronic inflammations. The company was founded by Annette M. Tobia on May 21, 1997 and is headquartered in Jenkintown, PA.	Health Technology